Cyproterone acetate (CPA) is a powerful antiandrogen and progestin with proven efficacy in managing prostate cancer, hirsutism, and as part of transgender hormone therapy. However, its use is restricted in the US due to concerns over liver toxicity and meningioma risks.
Mechanism
CPA targets the androgen receptor (AR) as a competitive antagonist, effectively blocking the action of testosterone and dihydrotestosterone (DHT). It also suppresses gonadotropin release through progesterone receptor activation, leading to a significant reduction in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which decreases testicular testosterone production. Additionally, CPA exhibits mild inhibition of 5α-reductase, enhancing its antiandrogen effects.
Research
Recent findings suggest that lower doses of CPA (10-12.5 mg/day) can effectively suppress testosterone levels similarly to higher doses. This aligns with the trend towards reducing exposure while maintaining efficacy, particularly in transfeminine hormone therapy.
Synergies
Combining CPA with estrogen therapy maximizes its effectiveness, not only suppressing testosterone but also enhancing feminization. Ben IQ evaluates YOUR labs and personal goals to tailor the ideal combination for optimal results.
Trade-Offs
While CPA offers considerable benefits for testosterone management, it carries risks including meningioma and hepatotoxicity, especially at higher cumulative doses. Personalized patient assessment and ongoing monitoring are crucial. Remember, YOUR unique situation requires YOUR specific data.